false 0001828522 0001828522 2024-01-29 2024-01-29 0001828522 eftr:CommonStock0.0001ParValuePerShare2Member 2024-01-29 2024-01-29 0001828522 eftr:WarrantsToPurchaseCommonStock1Member 2024-01-29 2024-01-29

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 29, 2024

 

 

eFFECTOR Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39866   85-3306396

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

142 North Cedros Avenue, Suite B

Solana Beach, California

   92075
(Address of principal executive offices)   (Zip Code)

(858) 925-8215

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common stock, $0.0001 par value per share   EFTR   Nasdaq Capital Market
Warrants to purchase common stock   EFTRW   Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Sec.230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Sec.240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 8.01 Other Events.

On January 29, 2024, eFFECTOR Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) and the minimum bid price matter is now closed. The letter was pursuant to a previous letter received on July 31, 2023 from Nasdaq the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), indicating, as previously reported, that the Company was not then in compliance with the minimum bid price requirement because its common stock had failed to maintain a minimum bid price of $1.00 or more for 30 consecutive business days.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    eFFECTOR Therapeutics, Inc.
Date: January 30, 2024     By:  

/s/ Michael Byrnes

    Name: Michael Byrnes
    Title:   Chief Financial Officer
v3.24.0.1
Document and Entity Information
Jan. 29, 2024
Document And Entity Information [Line Items]  
Amendment Flag false
Entity Central Index Key 0001828522
Document Type 8-K
Document Period End Date Jan. 29, 2024
Entity Registrant Name eFFECTOR Therapeutics, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39866
Entity Tax Identification Number 85-3306396
Entity Address, Address Line One 142 North Cedros Avenue
Entity Address, Address Line Two Suite B
Entity Address, City or Town Solana Beach
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92075
City Area Code (858)
Local Phone Number 925-8215
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Entity Ex Transition Period false
Common Stock 0.0001 Par Value Per Share 2 [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Common stock, $0.0001 par value per share
Trading Symbol EFTR
Security Exchange Name NASDAQ
Warrants To Purchase Common Stock 1 [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Warrants to purchase common stock
Trading Symbol EFTRW
Security Exchange Name NASDAQ
eFFECTOR Therapeutics (NASDAQ:EFTR)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more eFFECTOR Therapeutics Charts.
eFFECTOR Therapeutics (NASDAQ:EFTR)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more eFFECTOR Therapeutics Charts.